Diabetic Retinopathy Market Analysis, Demand And Outlook 2025- 2034

Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence

What Is the Estimated Market Size and CAGR of the Diabetic Retinopathy Market for the Period 2025–2029?
The diabetic retinopathy market size has grown strongly in recent years. It will grow from $8.61 billion in 2024 to $9.26 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population, increasing prevalence of diabetes, growing awareness about diabetic retinopathy, improved healthcare infrastructure, rising healthcare expenditure.

The diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to " $12.5 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to personalized medicine approaches, expansion of telemedicine services, development of novel therapeutic interventions, adoption of point-of-care testing, remote patient monitoring. Major trends in the forecast period include precision medicine in diabetic retinopathy treatment, increased focus on early detection and prevention, teleophthalmology services growth, rise in gene therapy research, continuous advancements in retinal imaging technology.

Get your free report sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12187&type=smp

Which Factors Are Contributing Most to the Expansion of the Diabetic Retinopathy Market?
The rising prevalence of diabetes is expected to propel the growth of the diabetic retinopathy market going forward. Diabetes refers to a long-term metabolic disease that causes high blood glucose levels. The rise in the prevalence of diabetes is mainly driven by overweight, obesity, genetics, and physical inactivity, whereas patients with diabetes have too much sugar in their blood, which can damage the retina, which is part of the eye that detects light and sends signals to your brain through a nerve in the back of eye. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%. The proportion of people meeting target HbA1c levels also reached 37.9%, the highest ever recorded by the National Diabetes Audit. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic retinopathy market.

What Are the Emerging Segments Driving Growth in the Diabetic Retinopathy Market?
The diabetic retinopathymarket covered in this report is segmented –

1) By Type: Proliferative Diabetic Retinopathy; Non-Proliferative Diabetic Retinopathy
2) By Treatment: Anti-VEGF Drugs; Intraocular Steroid Injection; Laser Photocoagulation; Vitreoretinal Surgery
3) By End-User: Hospitals; Ambulatory Surgical Centers; Other End Users

Subsegments:
1) By Proliferative Diabetic Retinopathy (PDR): Neovascularization; Vitreous Hemorrhage; Tractional Retinal Detachment
2) By Non-Proliferative Diabetic Retinopathy (NPDR): Mild NPDR; Moderate NPDR; Severe NPDR

What Are the Current Trends Influencing the Diabetic Retinopathy Market?
Technological advancements are a key trend gaining popularity in the diabetic retinopathy market. Major companies operating in the large volume parenteral market are adopting new technologies to sustain their position in the market. For instance, in July 2022, Baxter International Inc., a US-based healthcare company, launched Welch Allyn RetinaVue 100 Imager PRO in South Korea. These technologies are intended to allow for the detection of diabetic retinopathy in primary care settings. RetinaVue has proven to increase patient compliance for potentially life-saving annual diabetic retinal exams (DREs) by screening patients quickly and comfortably during a routine primary care visit.

Which Companies Hold a Prominent Position in the Diabetic Retinopathy Market?
Major companies operating in the diabetic retinopathy market include Pfizer Inc., F-Hoffmann-La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, Ellex Medical Lasers Ltd., Abbott Laboratories Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Icon Bioscience Inc., Allergan plc., Genentech Inc., Aurobindo Pharma, Santen Pharmaceutical Co. Ltd., Carl Zeiss Meditec AG, Valeant Pharmaceuticals International Inc., Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co. Ltd., IRIDEX Corporation, Alimera Science Inc., Kowa Company Ltd., Ocular Therapeutix Inc., Aerpio Pharmaceuticals Inc., Kodiak Sciences Inc., Oxurion NV, Graybug Vision Inc., Ampio Pharmaceuticals Inc.

Get the detailed diabetic retinopathy market report today
https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report

What Are the Fastest-Growing Regions in the Diabetic Retinopathy Market?
North America was the largest region in the diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company